Marcos C. Miranda,Elizabeth Kepl,Mary Jane Navarro,Chengbo Chen,Max Johnson,Kaitlin R. Sprouse,Cameron Stewart,Anne Palser,Adian Valdez,Deleah Pettie,Claire Sydeman,Cassandra Ogohara,John C. Kraft,Minh Pham,Michael Murphy,Sam Wrenn,Brooke Fiala,Rashmi Ravichandran,Daniel Ellis,Lauren Carter,Davide Corti,Paul Kellam,Kelly Lee,Alexandra C. Walls,David Veesler,Neil P. King

Abstract:We previously described a two-component protein nanoparticle vaccine platform that displays 60 copies of the SARS-CoV-2 spike protein RBD (RBD-NP). The vaccine, when adjuvanted with AS03, was shown to elicit robust neutralizing antibody and CD4 T cell responses in Phase I/II clinical trials, met its primary co-endpoints in a Phase III trial, and has been licensed by multiple regulatory authorities under the brand name SKYCovione TM . Here we characterize the biophysical properties, stability, antigenicity, and immunogenicity of RBD-NP immunogens incorporating mutations from the B.1.351 (β) and P.1 (γ) variants of concern (VOCs) that emerged in 2020. We also show that the RBD-NP platform can be adapted to the Omicron strains BA.5 and XBB.1.5. We compare β and γ variant and E484K point mutant nanoparticle immunogens to the nanoparticle displaying the Wu-1 RBD, as well as to soluble prefusion-stabilized (HexaPro) spike trimers harboring VOC-derived mutations. We find the properties of immunogens based on different SARS-CoV-2 variants can differ substantially, which could affect the viability of variant vaccine development. Introducing stabilizing mutations in the linoleic acid binding site of the RBD-NPs resulted in increased physical stability compared to versions lacking the stabilizing mutations without deleteriously affecting immunogenicity. The RBD-NP immunogens and HexaPro trimers, as well as combinations of VOC-based immunogens, elicited comparable levels of neutralizing antibodies against distinct VOCs. Our results demonstrate that RBD-NP-based vaccines can elicit neutralizing antibody responses against SARS-CoV-2 variants and can be rapidly designed and stabilized, demonstrating the potential of two-component RBD-NPs as a platform for the development of broadly protective coronavirus vaccines.

Design of a Stabilized RBD Enables Potently Neutralizing SARS-CoV-2 Single-Component Nanoparticle Vaccines

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates

Rapid Development of SARS-CoV-2 Receptor Binding Domain-Conjugated Nanoparticle Vaccine Candidate

Single-component, Self-Assembling, Protein Nanoparticles Presenting the Receptor Binding Domain and Stabilized Spike As SARS-CoV-2 Vaccine Candidates.

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

Vaccines: SARS‐CoV‐2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination (Adv. Mater. 50/2020)

RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2

A Single Dose SARS-CoV-2 Simulating Particle Vaccine Induces Potent Neutralizing Activities

Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2

Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2

Hydrogel‐Based Slow Release of a Receptor‐Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS‐CoV‐2

Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern

A bioengineered pseudovirus nanoparticle displaying SARS-CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS-CoV 2 challenge

Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

Inducing Enhanced Neutralizing Antibodies Against Broad SARS-CoV-2 Variants Through Glycan-Shielding Multiple Non-Neutralizing Epitopes of RBD

Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys

Development of Receptor Binding Domain (RBD)‐Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS‐CoV‐2 Delta and Other Variants

Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants